- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02648425
Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine
연구 개요
상태
정황
상세 설명
This is an open-label, Phase I, dose escalation study of ASLAN001 given in combination with Regimen A or Regimen B, in patients with metastatic solid tumors, eligible to receive the cisplatin/5-fluorouracil or cisplatin/capecitabine regimen.
Dose of ASLAN001 starts from 400mg BID; then, dose escalation to 500mg BID or dose de-escalation to 300mg BID will depend on DLTs observed in cohort.
Regimen A: Depends on preferred medical practice, Cohort 1A will receive ASLAN001 400 mg BID in combination with cisplatin 80 mg/m2 IV infusion and 5 fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks; or will receive ASLAN001 400 mg BID in combination with Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks.
Regimen B: Cohort 1B will receive ASLAN001 400 mg BID in combination with cisplatin 80 mg/m2 IV infusion and oral capecitabine 1,000 mg/m2 BID for 14 days every 3 weeks.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female patients 20 years of age or older at the time written informed consent is obtained.
Regimen A: Patients with metastatic solid tumors eligible for treatment with cisplatin and 5-fluorouracil. The standard dose and schedule of cisplatin and 5-fluorouracil will be according to the preference of investigators and institutions.
Regimen B: Patients with metastatic solid tumors eligible for treatment with cisplatin in combination with capecitabine.
- Patients with a partial gastrectomy may be allowed to participate in the study as long as they can take oral medications and meet all other inclusion/exclusion criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ and hematological function as evidenced by the following laboratory studies within 14 days prior to enrolment:
Hematological function, as follows:
- Absolute neutrophil count ≥ 1.5 x 109/L.
- Platelet count ≥ 100 x 109/L.
- Hemoglobin ≥ 9 g/dL.
Coagulation function, as follows:
- Partial thromboplastin time or activated partial thromboplastin time ≤ 1.5 x upper limit of normal (ULN) per institutional laboratory normal range.
- International normalized ratio ≤ 1.5.
Renal function, as follows:
• Creatinine clearance ≥ 50 mL/min as calculated by Cockcroft-Gault formula.
Hepatic function, as follows:
- Total bilirubin ≤ 1.5 x ULN.
- AST and ALT ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases are present).
Exclusion Criteria:
- Patients with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy.
- Patients receiving proton pump inhibitors or H2 antagonists for established, symptomatic gastro duodenal ulceration or gastroesophageal reflux disease.
- Patients with unresolved toxicities of grade 2 or more from prior anti-cancer therapies.
- Untreated or symptomatic central nervous system metastases. Patients with a history of brain metastases are eligible if definitive therapy has been administered (surgery and/or radiation therapy), there is no planned treatment for brain metastases, and the patient is clinically stable and is off corticosteroids for at least 2 weeks prior to enrolment.
- Major surgical procedures within 28 days prior to enrolment.
- Clinically significant cardiovascular diseases that are symptomatic or uncontrolled.
- Known positive test for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen.
- Pregnant or breast-feeding females.
- Patients who have hearing impairment, due to the potential for ototoxicity of cisplatin.
- Any history or presence of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease or any other condition which in the opinion of the Investigator could jeopardize the safety of the patient or the validity of the study results
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Regimen A / Amended Regimen A
Regimen A: Cisplatin + 5-fluorouracil ASLAN001 daily in combination with: Cisplatin 80 mg/m2 IV infusion for 1 day and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks for up to 6 cycles. Or Amended Regimen A: Cisplatin + 5-fluorouracil + leucovorin ASLAN001 daily in combination with: Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks for up to 6 cycles. |
ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
다른 이름들:
Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks; Or Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks. |
실험적: Regimen B
Regimen B: Cisplatin + capecitabine ASLAN001 daily in combination with: Cisplatin 60-80 mg/m2 IV infusion on Day 1 and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks for up to 6 cycles. |
ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
다른 이름들:
Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Safety and Tolerability of ASALN001
기간: First 2 cycles
|
Safety and tolerability as evaluated with: DLTs (in first 2 cycles); Maximum tolerated dose (MTD) of ASLAN001 in combination with cisplatin/capecitabine or cisplatin/5-FU will be determined. |
First 2 cycles
|
Safety and Tolerability of ASALN001
기간: Baseline to post-dose
|
Safety and tolerability as evaluated with: Adverse events. |
Baseline to post-dose
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Preliminary assessment of the efficacy
기간: Along the study duration
|
•To provide a preliminary assessment of the efficacy of ASLAN001 when given in combination in Regimen A or Regimen B as measured by the objective response rate (ORR).
|
Along the study duration
|
Pharmacokinetics profile (AUC) of ASLAN001
기간: Along the study duration
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with Regimen A or Regimen B. Pharmacokinetic parameters including, but not limited to area under the plasma concentration-time curve (AUC) from 0 to 6 hours (AUC0-6).
|
Along the study duration
|
Pharmacokinetics profile (Cmax) of ASLAN001
기간: Along the study duration
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with Regimen A or Regimen B. Pharmacokinetic parameters including, but not limited to maximum plasma concentration (Cmax).
|
Along the study duration
|
Pharmacokinetics profile (Cmin) of ASLAN001
기간: Along the study duration
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with Regimen A or Regimen B. Pharmacokinetic parameters including, but not limited to minimum (trough) plasma concentration (Cmin).
|
Along the study duration
|
Pharmacokinetics profile (RacAUC0-6) of ASLAN001
기간: Pharmacokinetic measurements will be from Cycle 1 Day 1 to Cycle 3 Day 1 (each cycle is 28 days for Amended Regimen A, and 21 days for Regimen A and B.
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with Regimen A or Regimen B. Pharmacokinetic parameters including, but not limited to accumulation ratio for AUC (RacAUC0-6).
|
Pharmacokinetic measurements will be from Cycle 1 Day 1 to Cycle 3 Day 1 (each cycle is 28 days for Amended Regimen A, and 21 days for Regimen A and B.
|
Pharmacokinetics profile (Tmax) of ASLAN001
기간: Along the study duration
|
To evaluate the pharmacokinetics of ASLAN001, when given in combination with
|
Along the study duration
|
공동 작업자 및 조사자
수사관
- 연구 의자: ASLAN Pharma, ASLAN Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
고형종양에 대한 임상 시험
-
AstraZeneca모병Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, 위암, 유방암 및 난소암스페인, 미국, 벨기에, 영국, 프랑스, 헝가리, 캐나다, 대한민국, 호주
ASLAN001에 대한 임상 시험
-
ASLAN Pharmaceuticals완전한
-
ASLAN Pharmaceuticals완전한
-
ASLAN PharmaceuticalsSyneos Health; bioRASI, LLC; CMIC Co, Ltd. Japan완전한담도암미국, 호주, 중국, 홍콩, 헝가리, 일본, 대한민국, 폴란드, 싱가포르, 스페인, 대만
-
National Cancer Centre, SingaporeNational Medical Research Council (NMRC), Singapore; ASLAN Pharmaceuticals모집하지 않고 적극적으로
-
ASLAN Pharmaceuticals완전한
-
National University Hospital, Singapore알려지지 않은